Neurotrope Inc (NASDAQ:NTRP) saw some unusual options trading on Wednesday. Stock traders acquired 1,187 call options on the stock. This represents an increase of 1,442% compared to the average volume of 77 call options.
Separately, ValuEngine downgraded Neurotrope from a “buy” rating to a “hold” rating in a research report on Monday, February 25th.
Shares of Neurotrope stock opened at $6.89 on Thursday. Neurotrope has a 52 week low of $3.33 and a 52 week high of $11.93.
Neurotrope (NASDAQ:NTRP) last announced its quarterly earnings data on Monday, March 11th. The company reported ($0.47) EPS for the quarter.
Institutional investors have recently made changes to their positions in the company. Eaton Vance Management purchased a new position in shares of Neurotrope in the 4th quarter valued at approximately $164,000. Raymond James & Associates purchased a new position in shares of Neurotrope in the 4th quarter valued at approximately $42,000. BlackRock Inc. increased its position in Neurotrope by 17.9% during the 1st quarter. BlackRock Inc. now owns 24,577 shares of the company’s stock valued at $134,000 after buying an additional 3,729 shares in the last quarter. MYDA Advisors LLC bought a new position in Neurotrope during the 1st quarter valued at approximately $690,000. Finally, Renaissance Technologies LLC increased its position in Neurotrope by 113.3% during the 1st quarter. Renaissance Technologies LLC now owns 159,447 shares of the company’s stock valued at $869,000 after buying an additional 84,700 shares in the last quarter. Institutional investors and hedge funds own 13.87% of the company’s stock.
Neurotrope Company Profile
Neurotrope, Inc, a biopharmaceutical company, focuses on the development of a product platform for the treatment of Alzheimer's disease. Its lead product candidate is bryostatin, a natural product isolated from a marine invertebrate organism, a bryozoan called Bugula neritina. The company also develops bryostatin for other neurodegenerative or cognitive diseases and dysfunctions, such as Fragile X syndrome, multiple sclerosis, and niemann-pick type C diseases.
Recommended Story: Compound Annual Growth Rate (CAGR)
Receive News & Ratings for Neurotrope Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Neurotrope and related companies with MarketBeat.com's FREE daily email newsletter.